Patents by Inventor Jane E. SCANLON

Jane E. SCANLON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240043410
    Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
    Type: Application
    Filed: September 3, 2021
    Publication date: February 8, 2024
    Inventors: Mark G. BOCK, David HARRISON, Jane E. SCANLON
  • Publication number: 20230083495
    Abstract: The present disclosure relates to compounds of Formula (I) and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
    Type: Application
    Filed: June 11, 2020
    Publication date: March 16, 2023
    Inventors: Mark G. BOCK, David HARRISON, Jane E. SCANLON
  • Publication number: 20220267300
    Abstract: The present disclosure relates to compounds of Formula (I) or (II): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
    Type: Application
    Filed: June 11, 2020
    Publication date: August 25, 2022
    Inventors: Mark G. BOCK, David HARRISON, Jane E. SCANLON
  • Publication number: 20220227715
    Abstract: The present disclosure relates to compounds of Formula (I) and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
    Type: Application
    Filed: June 11, 2020
    Publication date: July 21, 2022
    Inventors: Mark G. BOCK, David HARRISON, Jane E. SCANLON